SITC Updates

Immune Monitor - January 2026

By SITC Communications posted 5 days ago
A Message from the President As we begin 2026, I’m pleased to share that SITC’s 2025 Year in Review is now live. It reflects a year defined by both complexity and innovation, and highlights the scientific progress, educational growth, and collective impact made possible by our global community. I invite you to explore the Year in Review website and read my full letter below, where I reflect on our shared accomplishments and the momentum carrying us forward. Read the SITC Year in Review >> Remembering Dr. Ernest Borden SITC honors the memory of Dr. Ernest Borden, who passed away on Jan. 18, 2026. We are deeply grateful ...

Call for Comment: SITC Acute Leukemia CPG v2.0 Until Feb. 16

By Chuck Kolawole posted 6 days ago
MANUSCRIPT TITLE: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia v2.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Acute Leukemia (AL) Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia v2.0,” an update to the society’s 2020 CPG for this disease setting. The new AL manuscript is part of the broader catalogue of SITC Cancer ...

JITC Digest January 2026

By JITC Publications posted 13 days ago
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|Thank You to JITC Reviewers| Popular Archive Articles Letter from the Editor Hello JITC Readers, Indeed, “ it takes a village “ for JITC to receive, review, improve and then promote the important work in immuno-oncology that we have the privilege to consider and develop in our Journal . We express our gratitude to all our Section and Associate Editors as we head into this New Year. I would like to welcome the new editors joining us and also send a sincere thank you to those whose terms concluded at the end of last ...

Immune Monitor - December 2025

By SITC Communications posted 28 days ago
A Message from the President As 2025 draws to a close, I am humbled by the resilience of our community. Throughout the year, many of us faced disruption in our clinics and labs with the uncertain and shifting funding paradigm. However, thanks to each of you, 2025 was a year of remarkable progress for our community. Like our members, SITC’s leadership remained steadfast and future focused . At the biotech strategic meeting at the NYSE, we explored opportunities to advance TCEs, bispecifics and in vivo CAR T approaches. Our summit on expanding access to cell therapies for solid tumors brought together experts to examine pathways into the community ...

JITC Digest December 2025

By JITC Publications posted 12-17-2025
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| Popular Archive Articles Letter from the Editor Hello JITC Readers, The recent award of the Nobel Prize in Physiology or Medicine to Mary Brunkow, Fred Ramdsell and Shimon Sakaguchi (which I watched on a LinkedIn broadcast) highlighted for me the importance of fundamental research. This goes back to the spontaneous mutation observed by William and Liane Russell in male mice at the Oak Ridge National Laboratory in eastern Tennessee that had previously been part of the Manhattan Project in 1943. These mice were continuously bred and maintained ...

2025 ESMO IO Scientific Highlights

By Keegan Mager posted 12-12-2025
We are pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Immuno-Oncology Congress 2025, Dec. 10–11, 2025. Clinical and translational studies of neoadjuvant pembroluzmab and lenvatinib in patients with resectable early-stage lung cancer LBA1. Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME): Clinical results including multi-omic deconvolution of the TME from the INNWOP01 study Andreas Pircher (Innsbruck Medical University, Innsbruck, Austria) presented results from the INNWOP01 study a single-center ...

SITC Hosts "AI, Upcoming Technologies, and Potential Applications: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 12-10-2025
On December 2, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the tenth computational immuno-oncology webinar of series 5. This webinar discussed patient burden dynamics, serum, tumor genomic, and functional profiles contain valuable insights for cancer research. It demonstrated how AI, computational, and mathematical driven approaches can integrate these profiles to model the tumor-microenvironment interactions, discover novel IO targets and biotherapeutics, predict patient responses to immunotherapy, elucidate mechanisms of IO resistance, and develop therapies that exploit drug dosing and sequencing. ...

NEW! Myeloid Cells in Immuno-Oncology

By JITC Publications posted 12-02-2025
Edited by Dmitry I. Gabrilovich, MD, PhD; Jennifer Guerriero, PhD; and Judith A. Varner, PhD This JITC series aims to advance the biological understanding of myeloid cell biology within the tumor and strategies to modulate the function and activity of myeloid cells for anti-cancer therapy. Building upon the enthusiasm of the “ Targeting Myeloid Cells in Immuno-Oncology ” pre-conference workshop jointly sponsored by the Society for Immunotherapy of Cancer (SITC) and the Myeloid Network at the 2023 SITC Annual Meeting, this series will be comprised of viewpoint opinion commentaries on controversial topics in the field along with two review articles. ...

Oncology News Burst from the FDA: FDA Approves Durvalumab with FLOT for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

By SITC Communications posted 12-01-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Immune Monitor - November 2025

By SITC Communications posted 11-25-2025
A Message from the President SITC’s 40 th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025) marked a milestone for our society. We are deeply grateful to everyone who contributed to its success, including attendees, faculty, supporters, staff and volunteers. The meeting convened the immuno-oncology community in National Harbor, MD and virtually for several days of meaningful dialogue and groundbreaking science. With more than 1,300 abstracts presented, this year’s program demonstrated the continued momentum driving the field forward. Jennifer Wargo, MD, MMSc , delivered an excellent keynote address on the role of the microbiome in ...

Oncology News Burst from the FDA: FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By SITC Communications posted 11-24-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Oncology News Burst from the FDA: FDA Approves Epcoritamab-bysp for Follicular Lymphoma Indications

By SITC Communications posted 11-20-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

JITC Digest November 2025

By JITC Publications posted 11-19-2025
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|2025 JITC Mentorship Graduates | Popular Archive Articles Letter from the Editor Hello JITC Readers, It has been a busy period again in IO, with numerous conferences taking place in recent weeks. This past month I attended the 40 th Society for Immunotherapy of Cancer Annual Meeting in National Harbor, MD, and also had a chance to develop a session on “Imaging, Radiomics, and Integrated Biomarkers” as Co-Chair with Wim Vos, MSc, PhD. Shown is the meeting with the JITC Best Paper recipients for ...

SITC Hosts "Using Spatial Biology to Monitor Tumor Immune Interactions: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 11-19-2025
On November 13, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the ninth computational immuno-oncology webinar of series 5. This webinar reviewed some methods for extracting information on the tumor immune microenvironment from spatial imaging and spatial genomics assays. It also explored methods that relate the information obtained from different spatial assay types. View the webinar for free on-demand HERE .

SITC 2025 Science Coverage – Nov. 9

By Keegan Mager posted 11-10-2025
Preclinical development of macrophage-targeting CAR monocytes to improve immunotherapy outcomes in breast cancer 254. Targeting tumor-associated macrophages with CAR-monocytes as a first-in-class approach for cellular therapy in breast cancer Daniel Michaud (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States) presented a first-in-class platform of using CAR-monocytes to limit tumor-associated macrophage (TAMs) function in breast cancer tumors. TAMs have been well-characterized as inhibitory hurdles for T cell function in solid tumors. TAM-targeting CAR T cells showed some anti-cancer activity in mouse models of ovarian cancer, ...

SITC 2025 Science Coverage – Nov. 8

By Keegan Mager posted 11-09-2025
Development of QVT Score, a novel radiomic predictive biomarker of immunotherapy response and early survival outcomes in non-small cell lung cancer 66. QVT Score, a radiomic biomarker of tumor vascularity, enables immune checkpoint inhibitor (ICI) outcome prediction and early survival assessment in NSCLC Young Kwang Chae (Northwestern University, Chicago, IL, United States) presented the development of QVT Score, a novel radiomic biomarker of tumor vascularity, to predict immunotherapy response and survival outcomes in non-small cell lung cancer (NSCLC). This work builds upon previous studies of the relationship between tumor angiogenesis and immunotherapy ...

SITC 2025 Science Coverage – Nov. 7

By Keegan Mager posted 11-08-2025
Overall survival analysis of HARMONi-A: PD-1 x VEGF bispecific antibody ivonescimab with chemotherapy for non-small cell lung cancer 1348. Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment Xiuning Le (The University of Texas MD Anderson Cancer Center, Houston, TX, United States) presented the final and only overall survival (OS) analysis of HARMONi-A study investigating ivonescimab with chemotherapy versus chemotherapy in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations ...

Thank You to Our SITC Advocacy Day Volunteers

By SITC Advocacy posted 11-06-2025
On Nov. 5, 2025, dedicated volunteers from across the country joined us in Washington, DC, bringing their passion, expertise, and personal stories to the heart of our nation’s capital. Together, they met with numerous congressional offices to share how federal investment in cancer immunotherapy is changing lives, driving new treatments, supporting scientists, and bringing hope to patients and families everywhere. Their voices carried the momentum of our field, shining a light on why continued investment is so vital for the breakthroughs yet to come. #SITContheHill #Policy

Immune Monitor - October 2025

By SITC Communications posted 10-22-2025
A Message from the President I’m pleased to step in and provide this month’s update to the SITC community as we work through the temporary government shutdown together. While there is much to look forward to at SITC in the remainder of 2025, I am already looking ahead to the 2026 Spring Scientific program. This can’t-miss event will take place March 25–27, 2026, in Tucson, AZ, and virtually. The 2026 program will spotlight next-generation cellular therapies, T cell engagers, and novel combinations. Abstract submissions on these topics are now being accepted, and encore presentations are also welcome. Both poster and oral presentation opportunities are ...

SITC Hosts "Liquid Biopsy Approaches for Cancer Diagnosis and Monitoring: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 10-22-2025
On October 16, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the eighth computational immuno-oncology webinar of series 5. In this webinar, attendees explored the transformative potential of liquid biopsy approaches in cancer characterization, residual disease tracking and therapy response monitoring. Focusing on analyses of circulating tumor DNA (ctDNA), they reviewed how liquid biopsies provide unique insights into tumor dynamics and enable clinicians and researchers to make data-driven decisions that improve patient outcomes. The webinar also covered a comprehensive assessment of current and ...